The discovery of receptor activator for nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) as the fundamental factors in controlling osteoclast formation and activation has led to a greater understanding of bone biology over the past few years. Here we discuss the role of these molecules in immunology and skeletal remodelling and assess their involvement in diseases of bones and joints, including rheumatoid arthritis, Paget's disease, post-menopausal osteoporosis and malignant bone diseases. OPG has been identified as a potential anabolic agent for treating conditions in which there is net bone loss and is currently in Phase I clinical trials. This review examines the current evidence indicating that OPG increases bone mass, and discusses other possible beneficial effects of OPG, such as inhibition of tumour growth and relief from bone cancer pain. OPG can be measured in human serum, and numerous studies have suggested that increased or decreased serum concentrations of this molecule can indicate the existence of remodelling disorders. Here we discuss how abnormal serum OPG concentrations could potentially be used toindicate imbalances ofbone resorption and formation. The possible applications of serum OPG concentration as a marker for non-skeletal disease conditions are also considered.
Introduction
Receptor activator for nuclear factor kappaB (NF-KB) ligand (RANKL) is a member of the tumour necrosis factor (TNF) superfamily which. together with its receptor, receptor activator for NF-KB (RANK). and the decoy receptor osteoprotegerin (OPG) forms a group of proteins that regulate both skeletal remodelling and immune function. RANKL may exist as four isoforms: (1) bound to the cell membrane." (2) as a soluble form that is generated by post-translational processing from the cellular form by TNF-aconverting enzyme-like protease;' (3) as a primary secreted form; and (4) intracellularly '
In bone, RANKL-RANK interaction. together with stimulation by macrophage colony-stimulating factor (M-CSF). have recently been discovered to be the essential signals required to induce osteoclastogenesis. RANKL. OPG and M-CSF are produced by bone-forming osteoblasts, whereas osteoclasts and © 2002 The Association of Clinical Biochemists their precursors express RANK and the M-CSF receptor. Osteoclasts. the multinucleated cells that resorb bone. develop by fusion of haematopoietic cells of monocyte-macrophage lineage. and binding of soluble OPG to RANKL prevents RANKL-RANK interaction. inhibiting osteoclast formation (see Fig.1 ).T he levels of expression of RANKL and OPG may be modulated by numerous factors to control the rate of formation of osteoclasts, and the retention of the RANK receptor by mature osteoclasts also enables osteoclast resorption. and cell survival. to be controlled by these factors.v" Since the discovery of this trio of TNF family proteins. nearly all osteotropic hormones and local factors produced in the bone micro-environment that have previously been shown to influence osteoclast activity have been found to mediate their actions indirectly via RANKL/OPG expression.
Prior to its discovery as a major effector in bone. RANKL had been found to be expressed by activated T Figure 1 . Diagrammatic representation of the interactions resulting in osteoclast formation. Co-stimulation of osteoclast precursors by osteoblast-expressed receptor activator for nuclear factor kappaS ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) induces fusion of the precursor cells to form multinucleated osteoclasts. Osteoprotegerin (OPG), also produced by osteoblasts, acts as a decoy receptor to RANKL, preventing RANKL-RANK receptor interaction and inhibiting multinucleated osteoclast formation.
RANKL and OPG in bone and joint disease

Rheumatoid arthritis
As well as their roles in maintaining bone mass and immune cell function. RANKL. RANK and OPG have been found to be involved in the aetiology of many pathological conditions. Rheumatoid arthritis is characterized by a chronic inflammation of joints and infiltration by activated T cells and monocytes.!''!' Focal bone erosion occurs at sites of active inflammation. as well as in systemic osteopenla, causing joint deformation. pain and an increased risk of bone fractures.PP There is considerable evidence that lymphocytes and was named TNF-related activationinduced cytokine (TRANCE). Dendritic cells express the RANKL/TRANCE receptor. and interaction between RANKL/TRANCE and its receptor enhances dendritic cell survival and T-cell actlvatlon." In addition. RANKL-deficient mice display not only osteopetrosis and lack of tooth eruption arising from a complete absence of osteoclasts but exhibit defects in differentiation of T and B lymphocytes and lack all lymph nodes'? Activated T cells. as well as osteoblasts, can stimulate osteoclast formation and resorption via both membrane-bound and soluble RANKL expresslon," demonstrating one of the many important influences of immune cells on bone tissue. RANKL has also been detected in extraskeletal, non-lymphoidal tissues. where it has been suggested that it may influence cell survival and apoptosls."
Paget's disease
Paget's disease is characterized by localized areas of increased osteoclast activity. RANKL mRNA has been found to be elevated in a marrow stromal cell line developed from a pagetic lesion. and in pagetic marrow. relative to a normal stromal cell line and normal marrow. and was also higher in marrow from affected bones than in uninvolved bones from Paget's disease patlents.U Additionally. osteoclast precursors from these patients were shown to be more sensitive to RANKL than precursors from non-pagetic controls. 2 1.22 It therefore seems possible that the osteoclasts are involved in the removal of bone at these sites. In vitro studies have demonstrated that activated T cells can induce both formation and activation of osteoclasts.v'" and mice deficient in cytotoxic Tlymphocyte-associated molecule-d. in which T cells are spontaneously activated. display severe osteoporosis." Transfer of bone marrow stromal cells derived from these mice into RANKL-deficient mice caused osteoporosis. associated with an increased number of osteoclasts. This was prevented by administration of OPG. which suggests that T-cell-derived RANKL was sufficient to activate osteoclasts in vivo, in the absence of its expression by osteoblasts. 8 In mice in which rheumatoid arthritis was induced by intradermal injection of type II collagen. osteoclasts were present at sites of active bone erosion and adjacent to RANKL-producing. synovium-infiltrating mononuclear cells and chondrocytes.P In humans. RANKL expression has been localized to T cells within inflamed synovial tissues of rheumatoid arthritis patients. 14 · 16 but not in intact synovlum.F Synovial macrophages isolated from rheumatoid arthritis patients differentiated into osteoclasts in the presence of RANKL. 18 and synovial fibroblasts derived from patients with rheumatoid arthritis supported osteoclast formation via RANKL expression.l" Immunohistochemical studies revealed that osteoclasts in joints affected by rheumatoid arthritis were located both in areas where RANKL expression was highest and in sites of bone tnvaston.F Whereas RANKL is higher in areas affected by rheumatoid arthritis. OPG concentrations are lower in the synovial fluid of these patients." which increases the RANKL:OPG ratio. Recombinant OPG completely inhibits the resorptive activity of osteoclasts formed from cells isolated from the pannus and synovial membrane regions of rheumatoid arthritis-affected [olnts.r" suggesting that this inhibitor of RANKL may prevent bone erosion in rheumatoid arthritis joints. Taken together. this evidence strongly supports a role for the involvement of RANKL expressed by both T cells and fibroblastic cells in the pathogenesis of rheumatoid arthritis-related bone disease.
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Osteoclast precursors combination of enhanced RANKL expression in affected bones. and increased sensitivity of pagetic osteoclast precursors. may contribute to the abnormally high number of osteoclasts in pagetic lesions. We. and others.P have also observed lower serum OPG concentrations in Paget's patients than in individuals without this disease. which would further alter the RANKL:OPG ratio and encourage osteoclast formation and activation.
Post-menopausal osteoporosis
Hormonal changes that affect the RANKL:OPG ratio may play a large role in the development of osteoporosis. In vitro. OPG expression by human osteoblastic cells was increased after oestrogen stlrnulatlon.i" and in vivooestrogen has been shown to increase serum OPG concentratlons.r" Both RANKL expression and the responsiveness of osteoclast precursors to RANKL were inhibited by oestrogen in vitro. 26 . 27 Conversely. RANKL expression was increased and OPG decreased by oophorectomy in mice. and this was prevented by oestrogen replacement." It would appear that oestrogen deficiency following the menopause is associated with elevated RANKL and reduced OPG expression. resulting in net bone loss.
Malignant bone diseases Osteosarcoma
These tumours develop through malignant transformation of osteoblastic cells. High OPG mRNA levels have been detected in certain osteosarcoma cell ltnes.I? and a preliminary report has shown that RANKL mRNA is often absent from bone specimens isolated from osteosarcomas. 30 These studies suggest that the ratio of RANKL:OPG may in some way influence osteosarcoma development. This altered RANKL:OPG expression and the resulting inhibition of osteoclast activity may allow for more rapid osteoblast proliferation. although this scenario is somewhat speculative.
Giant-cell tumour
Giant-cell tumours (GCTs) develop, at least in part. through unregulated over-expression of RANKL/ RANK. resulting in local bone destruction. They contain large, multinucleated osteoclast-like 'giant cells' that express higher levels of RANK than normal osteoclasts." and the stromal cells in these tumours express RANKL mRNA abundantly. U Together. these effects result in increased osteoclast activity.
Bone metastases
Osteolytic bone metastases and humoral hypercalcaemia of malignancy (HHM) frequently occur after breast carcinoma has developed. Breast cancer cells can secrete parathyroid-hormone-related protein.
which increases RANKL and decreases OPG expression by osteoblasts, 33 resulting in enhanced osteoclast differentiation and resorption. 33 . 34 It could be argued that these tumour-induced changes in protein expression that result in increased resorption of bone may create cavities in bone where tumours are able to expand. Bone metastases may also occur in cases of prostate carcinoma. but these are often sclerotic where there is an increase in bone formation. OPG mRNA levels have been found to be significantly higher in prostate carcinoma cells than in healthy prostate ttssue.l" which again indicates that the RANKL:OPG ratio may affect tumour growth by inhibiting osteoclast activity to allow increased osteoblast proliferation. as is thought might occur in osteosarcomas. Osteosarcomas and prostate carcinoma skeletal metastases grow as similar osteoblastic tumours in bone.
OPG as a therapeutic agent
A recent study 36 reported that in post-menopausal women a single subcutaneous dose of OPG of up to 3 rug/kg decreased the biochemical markers of bone resorption (urinary N-telopeptide and deoxypyr-Idlnoline, which are both collagen degradation products). within 12 h after administration. and the effect was still apparent 6 weeks later. 36 The reduction in products of bone resorption was attributed to a direct inhibition of osteoclast resorption by OPG. Although this is the first study to report involving human subjects. there is substantial evidence from animal studies to support these findings. OPG injected into normal rats specifically acted on bone tissues to increase bone mineral density (BMD) associated with a decrease of active osteoclast number.F Bone mass was also increased in transgenic mice over-expressing OPG. 38 and this same study reported that OPG could prevent oophorectomy-induced bone loss in rats.
There is little doubt that OPG. currently in Phase I clinical trials. is a potential much-needed anabolic agent for treating conditions in which bone loss occurs. such as post-menopausal osteoporosis. rheumatoid arthritis and myeloma. At present. other anabolic agents shown to be effective. which may become clinically available in the future. include fluoride and the intermittent administration of parathyroid hormone (PTH). Combined use of OPG and PTH in ovariectomized rats has shown an additive effect on bone mass. 39 OPG treatment inhibited resorption of bone slices by GCT in vitro. and reduced the formation of multinucleated osteoclasts from precursors within the tumour.t" Although these effects have yet to be investigated in vivo. they provide promising evidence for future prevention of GCT growth. In a murine model of osteosarcoma. OPG prevented cancerinduced skeletal destruction and skeletal pain (deduced from behavioural changes and neurochemical reorganization of the spinal cord), which suggests a potential role for OPG in managing bone cancer pain.41.42 Treatment with OPG in mice with HHM resulted in reduced tumour-induced increases in bone resorption and the return of blood ionized calcium concentrations to within the reference range.43.44
Morony et at. have also shown that OPG dosedependently decreased formation of skeletal metastases in mice following systemic injection of tumour cells." Bone lesions were undetectable in mice subjected to the highest concentration of OPG. Whilst OPG neutralizes RANKL, it also serves as a weak decoy receptor for TNF-related apoptosisinducing ligand (TRAIL). 46 There is some concern that OPG therapy may inhibit tumour apoptosis and result in accelerated tumour growth, although there is no evidence to support this. The design of inhibitors that act specifically to block the interaction only between RANKL and RANK may overcome this potential problem.
Measurement of OPG as a biochemical marker of disease
Measurement of serum OPG was initially reported from apparently healthy volunteers using an enzymelinked immunosorbent assay. Low concentrations of OPG (in the region of 0'2 ng/rnl.) could be detected in the serum of all subjects. These concentrations were found to be slightly higher in women than in men, and exhibited a small age-related increase that was estimated at 0·002 ng/rnl, per year. 47 Serum concentrations of OPG were subsequently found to be significantly higher in post-menopausal women with osteoporosis than in age-matched controls, and in these patients OPGwas higher in those with low bone rnass.t" Higher concentrations of serum OPGwere also correlated with increased biochemical markers of bone resorption (urinary pyridinoline and deoxypyridinoline). These findings suggested that OPGis increased in conditions where bone resorption predominates over bone formation, as a somewhat ineffective compensatory mechanism to prevent further bone loss. Why loss of bone should still occur despite higher levels of OPG is unknown, but could be explained by the higher levels of RANKL observed in conditions of oestrogen deflclency" Further studies have confirmed the negative correlation of serum OPG concentrations with BMD in post-menopausal women.?" Conversely, in a study involving male subjects, a negative correlation of serum OPG concentrations with biochemical markers of bone resorption was recently reported. 50 These Ann Clin Biochem 2002; 39: 551-556 discrepancies are confusing, and further work is required to clarify the association between serum OPG concentration and BMD before any firm conclusions can be drawn. The study of male subjects also reported 50 that serum OPG was positively correlated with free testosterone and free oestradiol concentrations and negatively correlated with serum PTH. Serum OPG decreased after administration of human PTH to post-menopausal women with osteoporosis.P findings that are consonant with data suggesting an inverse correlation between gene expression of OPG by bone cells and serum PTH in post-menopausal women. 51 Low serum OPGconcentrations observed in cases of Paget's disease again indicate how imbalances in resorption and formation of bone result in abnormal serum OPG concentrations. Osteoblast activity is increased in Paget's disease. whereas osteoblasts are less active in osteoporosis. Increased osteoclast resorption occurs in both conditions despite the very different serum OPG concentrations, indicating that no direct association between osteoclast activity and serum OPGconcentrations can be drawn.
Higher serum OPG concentrations have been detected in patients with persistent immune activation, such as HIV, and common variable immunodeficiency.52 This observation was positively correlated with serum TNF-O(, which is known to induce OPG production in vitro. This provides a further example of an interaction that occurs between immune and bone cells because of their common expression of RANK, RANKL and OPG.
In addition to its potential use as an indicator of BMD and immune disease. serum OPG measurement may be a useful marker of diabetes and vascular calcification. In a recent study, serum OPG was found to be 30% higher in women with diabetes, and higher concentrations were also associated with cardiovascular mortality,53 which highlights the role of OPG in non-skeletal tissues and serves as a reminder that. in addition to bone, OPGhas effects on and is produced by other tissues, any of which may contribute to its overall serum concentration.
Conclusion
The identification of RANKL, RANK and OPG has resulted in major advances in the understanding of basic bone biology and immunology, and provided a potential molecule (OPG or a similar engineered protein) for the treatment of bone disorders. OPG may prove to be an effective anabolic treatment for reduced bone mass. management of cancer-induced bone pain, and prevention of the development of skeletal metastases and HHM. In addition to its therapeutic applications, OPG may become a valuable biochemical marker of a number of disorders. High OPG concentration may become an indicator of excessive bone resorption and decreased BMD. whereas low serum OPG concentration may indicate the presence of Paget's disease. Adverse events associated with diabetes and diseases of the immune and cardiovascular system may also be detected by measurement of OPG.
Note added in proof
In patients with myeloma bone disease. current data suggest that malignant plasma cells may cause a local increase in the ratio of RANKL to OPG leading to osteoclast activation and lytic lesions. 54 Murine models have been used where recombinant OPG has been given to animals with established myeloma. resulting in preservation of cancellous bone and inhibition of osteoclast formation. 55 Recently, phase 1 clinical studies have reported [Am Soc Clin Oncol abstract 3227, Blood 2001; 98:(1)] describing significant reduction in bone resorption. equivalent to that seen with current bisphosphonates, when recombinant OPG was given to patients with myeloma and proven bone disease.
